Viruses and other intruders.

– It’s been some time that excess body fat, abdominal fat in particular, the production of ‘ pro-inflammatory ‘ immune cells that circulate in the blood and can bodies body known solves In addition, other inflammatory immune cells such as macrophages known. Activated within fat tissue. Drawn attention to The recent study examined obese people with type 2 diabetes or pre-diabetes, a diet of between 1000 and 1600 calories per day for 24 weeks were limited. The gastric band has been to be carried out after 12 weeks to help food intake. Food intake. The study determined the effects of weight loss on immune cells.. The immune system consists of many different types of cells that are made to protect the body against bacteria, viruses and other intruders.

The new tensions on the outbreak, only two days after the city’s first confirmed the death of a patient with swine flu. Meanwhile, in the midst of a new group of school closures and revived discussions about whether the World Health Organization should raise the pandemic alert level to the highest level, there is a new level of concern over the still mysterious swine flu virus.Ponatinib in the in Phase 2 PACE trial in patients with resistant or intolerant to CHICAGO and Ph+ ALL.. About Ponatinib – discovers sintering at ARIAD, exists. An investigational therapy pan – BCR-ABL inhibitor the also inhibit other tyrosine kinases selectively defined, including the of a specific mutation of FLT3 is called the internal tandem duplication . The primary target has of Ponatinib BCR-ABL, a tyrosine kinase, is not normal in chronic myelocytic leukemia and Philadelphia chromosome – positive acute lymphoblastic leukemia . Ponatinib ARIAD has been through that computing and structural – based drug design platform type activity from BCR-ABL very high effectiveness and broad specificity. Ponatinib seek not only virgin BCR-ABL , but also its isoforms, the mutations carrying a resistance to treatment with current tyrosine kinase inhibitors, including the mutation of T315I , for which no effective treatment exists.

The results patients with FLT3 – positively AML is based to a cohort of patients at ongoing phase 1 study of Ponatinib to haematologic malignancies. Was well tolerated, AML patients were given 45 mg per day Ponatinib.